Published in J Neurol Neurosurg Psychiatry on August 01, 1996
Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry (1999) 1.53
In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging. J Neurol Neurosurg Psychiatry (2000) 1.11
Correlations among brain gray matter volumes, age, gender, and hemisphere in healthy individuals. PLoS One (2011) 1.04
Magnetisation transfer ratio of normal brain white matter: a normative database spanning four decades of life. J Neurol Neurosurg Psychiatry (1997) 1.02
Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry (2006) 0.92
A magnetization transfer imaging study of corpus callosum myelination in young children with autism. Biol Psychiatry (2012) 0.80
Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci (1999) 0.77
Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry (1959) 6.64
Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology (1992) 2.41
Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol (1994) 1.35
Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR Am J Neuroradiol (1995) 1.22
Magnetisation transfer ratios and transverse magnetisation decay curves in optic neuritis: correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry (1995) 1.21
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Detection and modeling of non-Gaussian apparent diffusion coefficient profiles in human brain data. Magn Reson Med (2002) 3.53
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Ethnic differences in incidence of stroke: prospective study with stroke register. BMJ (1999) 3.12
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol (2001) 2.95
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Necessity of routine chest roentgenography after thoracentesis. Ann Intern Med (1996) 2.76
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Technique for measuring hippocampal T2 relaxation time. AJNR Am J Neuroradiol (1997) 2.65
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
The persistent vegetative state. BMJ (1995) 2.35
Management of acute optic neuritis. Lancet (2002) 2.33
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Test liquids for quantitative MRI measurements of self-diffusion coefficient in vivo. Magn Reson Med (2000) 2.14
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
Asymptomatic microscopic hematuria. J Urol (1980) 2.11
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (1990) 1.99
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
The chemical composition of the cell wall of Chlamydomonas gymnogama and the concept of a plant cell wall protein. J Cell Biol (1974) 1.95
Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol (1987) 1.93
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
EEG-triggered functional MRI of interictal epileptiform activity in patients with partial seizures. Brain (1999) 1.88
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet (1991) 1.86
Factors influencing PCR detection of viruses in cerebrospinal fluid of patients with suspected CNS infections. J Neurol Neurosurg Psychiatry (2005) 1.82
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry (2000) 1.81
Respiratory arrest: a complication of cerebellar ectopia in adults. J Neurol Neurosurg Psychiatry (1988) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Primary progressive multiple sclerosis. Brain (1997) 1.80
Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. Magn Reson Imaging (2002) 1.80
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 1.69
Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain (1994) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology (1998) 1.62
Diffusion tensor imaging in patients with epilepsy and malformations of cortical development. Brain (2001) 1.60
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology (1994) 1.60
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2005) 1.59
High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. J Neurol (2003) 1.59
Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology (1998) 1.58
Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology (2001) 1.58
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology (1999) 1.58
Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology (2001) 1.58
The British Isles survey of multiple sclerosis in twins. Neurology (1994) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain (1999) 1.56
Functional magnetic resonance imaging of regional brain activity in patients with intracerebral arteriovenous malformations before surgical or endovascular therapy. J Neurosurg (1996) 1.55
Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain (2007) 1.55
Brain structure and neurocognitive and behavioural function in adolescents who were born very preterm. Lancet (1999) 1.54
Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. Brain (2006) 1.53
Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry (1999) 1.53